AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Inclusion Criteria:

* 1、BCMA positive accompanied by refractory/relapsed and resistance;
* 2、Patients with the tumor load is high and cannot be transplanted directly, before transplantation. Reduce the load through CAR-T treatment to prepare for transplantation;
* 3、Patient relapses after transplantation,donor lymphocyte infusion Invalid. The donor cells in the recipient body can be used or the donor cells can be collected directly.Prepare CAR-T to prevent recurrence and induce relapsing;
* 4、Repeated MRD (+) refractory drug resistant cases;
* 5、Male or female, 30-75 years old;
* 6、Anticipated survival time more than 12 weeks
* 7、Transplant subjects, regardless of their previous treatment, are eligible for inclusion after relapse；
* 8、Patients had a negative urine pregnancy test before the start of administration and agreed to take effective contraceptive measures during the test period until the last follow-up;
* 9、Those who voluntarily participate in the trial and sign the informed consent form

Exclusion Criteria:

* 1、Patients with the history of epilepsy or other CNS disease；
* 2、Patients with prolonged QT interval time or severe heart disease；
* 3、Pregnant or breastfeeding;
* 4、Active infection with no cure;
* 5、Patients with active hepatitis B or C infection;
* 6、Previously treated with any genetic therapy;
* 7、The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
* 8、Serum creatinine \> 2.5mg/dl or ALT / AST \> 3 times ULN or bilirubin \> 2.0mg/dl;
* 9、Those who suffer from other uncontrolled diseases are not suitable to join the study;
* 10、HIV infection;
* 11、Any situation that the researchers believe may increase the risk of patients or interfere with the test results.